Konruns released its performance for the first three quarters, with a net profit attributable to the parent company of 128 million yuan, a year-on-year increase of 13.19%Zhitong·Oct 29, 2025 at 11:44 AM603590+0.88%
Konruns: Plans to repurchase company shares for 50 million to 100 million yuanZhitong·Oct 15, 2025 at 07:58 AM603590+0.88%
A-share innovative drug concept stocks fluctuated lower, with BETTA PHARMACEUTICALS falling over 10%, Jincheng Pharm, Konruns, Baillie Tianheng, Olymvax Biopharmaceuticals, and CCHT all dropping more than 5%Zhitong·Oct 14, 2025 at 01:11 AM300233+1.82%000661+0.63%
Konruns: KC1036 combined with PD-1 antibody and platinum-based chemotherapy has been approved for clinical trials as a first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinomaZhitong·Sep 29, 2025 at 07:51 AM603590+0.88%
Innovative drug concept stocks surged and then fell back, with Mengke Pharmaceutical dropping over 10%, BrightGene, Bio-S falling over 7%, and YKYY, Konruns, EASTON BIOPHARMACEUTICALS, Fushine among those with the largest declinesZhitong·Sep 25, 2025 at 12:43 AM688166+3.49%301096+5.17%
Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit upZhitong·Sep 14, 2025 at 08:43 PM603127+3.72%061270.00%
Konruns: KC1036 included in the Drug Review Center's "Starlight Program" pilot projectZhitong·Sep 5, 2025 at 02:42 AM603590+0.88%
Konruns' controlling shareholder plans to reduce holdings by no more than 3%Zhitong·Sep 5, 2025 at 02:39 AM603590+0.88%
Konruns: There is no significant information that should be disclosed but has not been disclosedZhitong·Sep 1, 2025 at 05:18 AM603590+0.88%
The concept of innovative drugs has risen again, with Chemexpress up over 15%Zhitong·Aug 29, 2025 at 12:16 AM688131+1.79%603590+0.88%
Konruns: Executives plan to reduce holdings by no more than 0.22%Zhitong·Aug 27, 2025 at 05:11 AM603590+0.88%
Konruns' subsidiary plans to participate in the Series E financing of Yourui Cayman with 150 million yuanZhitong·Jul 22, 2025 at 06:35 AM603590+0.88%
The biopharmaceutical sector experiences a volatile rebound, with Konruns hitting the daily limitZhitong·Jul 21, 2025 at 08:52 PM603590+0.88%
Konruns Pharmaceuticals hit the daily limit up during trading, with an increase of 10.0% and a transaction volume exceeding 500 million yuanZhitong·Jul 18, 2025 at 01:05 AM603590+0.88%
The concept of innovative drugs fluctuates and rebounds, ALK hits the limit and reaches a historical highZhitong·Jul 18, 2025 at 12:50 AM002940+3.97%002550+0.15%
